<DOC>
	<DOCNO>NCT01499771</DOCNO>
	<brief_summary>This study assess relative bioavailability 80 mg Atorvastatin Calcium Tablets ( contain atorvastatin calcium equivalent 80 mg atorvastatin ) manufacture OHM Laboratories , Inc. , USA ( A subsidiary Ranbaxy Pharmaceuticals. , USA ) compare 80 mg LIPITOR® Tablets ( contain atorvastatin calcium equivalent 80 mg atorvastatin ) distribute Parke Davis , Division Pfizer Inc. , USA follow single oral dose ( 1 x 80 mg tablet ) healthy adult subject administer fed condition .</brief_summary>
	<brief_title>A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fed Conditions</brief_title>
	<detailed_description>This open-label , balance , randomize , two-period , two-treatment , two-sequence , single-dose crossover bioequivalence study feed condition . The total duration study , screen study exit , approximately 8 week least 14-day washout period dos . At study check-in , subject report clinical site least 36 hour prior Day 1 dosing require stay 24 hour Day 1 dosing . Blood sample collection obtain within 90 minute prior dose ( 0 hour ) dose administration 0.333 , 0.667 , 1 , 1.25 , 1.5 , 1.75 , 2 , 2.25 , 2.5 , 2.75 , 3 , 3.5 , 4 , 6 , 8 , 10 , 12 , 16 , 24 , 36 , 48 , 60 , 72 , 96 hour . A total 25 blood sample collect per study period total 50 sample 150 mL total volume .</detailed_description>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>1 . Informed nature study , agree , able read , review , sign inform consent document prior Period I dose . The informed consent document write English , therefore volunteer must ability read communicate English . 2 . Completed screen process within four week prior Period I dose . 3 . Healthy male female , 18 year age old time dose . 4 . Body mass index ( BMI ) 18 32 kg/m2 , inclusive , weigh least 110 lb . 5 . Generally healthy document medical history , physical examination ( include limit evaluation cardiovascular , gastrointestinal , respiratory , central nervous system ) , vital sign assessment , 12lead ECG , clinical laboratory assessment , general observation . Any abnormalities/deviations acceptable range might consider clinically relevant study physician investigator evaluate individual case , document study file , agree upon principal investigator ( subinvestigator ) prior enrol subject study . 6 . Female subject : postmenopausal status ( menses ) least one year &lt; 55 year age document FSH level ≥ 40 mIU/mL ; , sterile [ surgically ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) Essure® Procedure ] . Fe Female subject surgically sterile provide documentation bilateral tubal ligation , bilateral oophorectomy , hysterectomy prior Period I dose . The Essure® Procedure must insert least 3 month prior documentation Essure® confirmation test prior Period I dose . 1 . Reported receiving investigational drug within 28 day prior Period I dose . 2 . Reported presence history clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease determine clinical investigator ( ) . 3 . Clinical laboratory test value outside accepted range confirm reexamination deem clinically significant . 4 . When confirm upon additional testing , demonstrate reactive screen hepatitis B surface antigen , hepatitis C antibody , HIV antibody . 5 . Reported clinically significant illness 28 day prior Period I dose ( determined clinical investigator ) . 6 . Demonstrated positive drug screen alcohol breath test . 7 . Reported history allergic response ( ) atorvastatin related drug . 8 . Reported history clinically significant allergy include food drug allergy . 9 . Reported history drug alcohol addiction abuse within past year . 10 . Reported donate blood within 28 day prior Period I dose . All subject advise donate blood four week complete study . 11 . Reported donate plasma ( e.g . plasmapheresis ) within 14 day prior Period I dose . All subject advise donate plasma four 12. week complete study . 13 . Reported intolerance direct venipuncture . 14 . Reported difficulty fast consume standardized meal . 15 . Reported difficulty swallow table capsule whole . 16 . Pregnant , lactating , breastfeeding , intend become pregnant course study ( female ) . 17 . Demonstrates positive pregnancy screen ( female ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>